CV Sciences (CVSI) AI Stock Analysis

• Market Cap: $10.60M
• Dividend Yield: N/A
• Average Volume (3M): 246.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -8.04%
• EPS Growth: 47.02%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 184,263,660
• 10 Day Avg. Volume: 158,629
• 30 Day Avg. Volume: 246,649
• PEG Ratio: 0.01
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -6.75
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.74
• Enterprise Value/Gross Profit: 1.22
• Enterprise Value/Ebitda: -9.41
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $0.06 ▼(-28.89% Downside)

CV Sciences is currently facing significant financial challenges, with declining revenues and negative profit margins being the most impactful factors. While technical indicators show some positive momentum, the overall financial health and valuation of the company remain weak. The company's strategic initiatives and product introductions offer some potential for future improvement, but current risks are substantial.

Positive Factors

Product Innovation

The introduction of new products can drive organic growth and enhance market position, potentially increasing revenue and shareholder value.

Gross Margin Stability

Sustaining a strong gross margin indicates effective cost management and pricing power, supporting long-term profitability.

Regulatory Engagement

Proactive engagement in regulatory changes can help shape favorable market conditions and secure long-term business viability.

Negative Factors

Revenue Decline

Continued revenue decline can weaken market position and limit resources for growth initiatives, impacting long-term sustainability.

High Leverage

High leverage can strain financial flexibility and increase vulnerability to economic downturns, affecting long-term stability.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiencies and limits the ability to invest in growth, impacting future prospects.

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. (CVSI) is a biotechnology company focused on the research, development, and commercialization of products derived from hemp extract, particularly those containing cannabidiol (CBD). Operating primarily in the wellness and pharmaceutical sectors, CV Sciences offers a range of products including dietary supplements, topical applications, and pharmaceutical formulations aimed at promoting health and well-being. The company is dedicated to providing high-quality, science-backed products that leverage the therapeutic potential of cannabinoids.

How the Company Makes Money

CV Sciences generates revenue through multiple streams, primarily by selling its consumer products under the brand name PlusCBD Oil. This includes a variety of CBD-infused dietary supplements, oils, and topical products which are sold through various channels such as retail stores, e-commerce platforms, and direct-to-consumer sales. Additionally, CV Sciences is engaged in the development of pharmaceutical products, particularly focusing on prescription medications that utilize CBD for therapeutic purposes. The company benefits from strategic partnerships with retailers and health product distributors, which help expand its market reach. Furthermore, the growing consumer interest in CBD products and the increasing legalization of hemp-derived products across various jurisdictions contribute to the company's revenue growth.

CV Sciences Financial Statement Overview

Summary

CV Sciences is facing significant financial challenges, with declining revenues, negative profit margins, and cash flow issues. The balance sheet shows high leverage and low equity, posing potential financial stability risks. Overall, the company needs strategic improvements to return to profitability and improve cash flows.

Income Statement

The company has faced a declining revenue trend over the years, with a notable drop from 2019 to 2024. Gross profit margins have decreased significantly, indicating cost pressure. The EBIT and net profit margins are negative, reflecting operational inefficiencies and consistent net losses.

Balance Sheet

The company exhibits a high debt-to-equity ratio, indicating potential leverage risks. The equity ratio is low, highlighting limited funding from shareholders relative to total assets. However, there has been a reduction in total liabilities over time, which is a positive sign.

Cash Flow

Cash flow from operations has been consistently negative, pointing to cash generation challenges. Free cash flow is also negative, indicating a lack of surplus cash after capital expenditures. The operating cash flow to net income ratio suggests operational struggles.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.11M	15.71M	16.00M	16.20M	20.05M	24.43M
Gross Profit	6.76M	7.17M	7.08M	5.55M	8.62M	11.01M
EBITDA	-873.00K	-1.86M	3.85M	-5.66M	-14.00M	-21.72M
Net Income	-1.48M	-2.39M	3.10M	-8.21M	-15.55M	-22.28M
Balance Sheet
Total Assets	7.00M	7.93M	26.35M	12.74M	18.07M	30.63M
Cash, Cash Equivalents and Short-Term Investments	381.00K	454.00K	1.32M	611.00K	1.38M	4.02M
Total Debt	860.00K	779.00K	442.00K	1.53M	922.00K	7.77M
Total Liabilities	5.46M	6.13M	23.44M	13.51M	14.52M	19.41M
Stockholders Equity	1.54M	1.79M	2.90M	-777.00K	3.54M	11.21M
Cash Flow
Free Cash Flow	-65.00K	-879.00K	2.25M	-1.89M	-7.52M	-8.36M
Operating Cash Flow	42.00K	-861.00K	2.25M	-1.89M	-7.49M	-7.30M
Investing Cash Flow	-122.00K	-28.00K	-156.00K	0.00	-35.00K	-1.06M
Financing Cash Flow	-256.00K	32.00K	-1.39M	1.12M	4.37M	3.27M

CV Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.28 is Neutral, neither overbought nor oversold. The STOCH value of 40.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVSI.

CV Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CVSI	46 Neutral	$10.60M	-5.88	-79.25%	―	-8.04%	47.02%
FLGC	46 Neutral	$5.49M	-0.22	-37.38%	―	-22.60%	53.82%
IMCC	45 Neutral	$7.77M	-1.82	-93.87%	―	-0.74%	81.49%
YCBD	40 Underperform	$14.25M	-0.43	-44.42%	―	-1.50%	80.17%
COSM	40 Underperform	$19.61M	-0.73	-63.82%	―	―	―
IXHL	39 Underperform	$142.16M	-0.37	-114.52%	―	-86.05%	24.17%

CV Sciences Corporate Events

CV Sciences Reports Q3 2025 Financial Results

On November 13, 2025, CV Sciences reported its financial results for the third quarter of 2025, showing a revenue of $3.3 million, a decline from the previous year due to lower sales volume and regulatory challenges. Despite the revenue drop, the company maintained a healthy gross margin of 48.5% and introduced new products, aiming for organic growth and strategic M&A opportunities to enhance revenue and shareholder value. The company also addressed recent legislative changes affecting the hemp industry, expressing disappointment but seeing an opportunity to influence future regulations.

CV Sciences Secures $600,000 Promissory Note Agreement

On October 6, 2025, CV Sciences, Inc. entered into a note purchase agreement with an institutional investor, resulting in the issuance of a secured promissory note worth $600,000. The transaction, which closed on October 7, 2025, provided the company with net proceeds of $300,000 after deductions. The note is secured by the company’s assets and intellectual property, with repayment terms set to begin in April 2026 and a maturity date in April 2027. The agreement includes provisions for events of default, which could lead to increased liabilities for the company.